Compare Box Inc (BOX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs BIO-TECHNE Corp — how do they compare? Box Inc trades at $30.49 (market cap $4.16B), while BIO-TECHNE Corp trades at $71.46 (market cap $11.10B). The key difference: BIO-TECHNE Corp is far larger — about 2.7× Box Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Box Inc pays none. Which is the better fit depends on your goals.
| BOX | TECH | |
|---|---|---|
Market Cap | $4.16B | $11.10B |
Sector | Technology | Health |
52-Week High | $33.55 | $71.38 |
52-Week Low | $21.37 | $43.31 |
Enterprise Value | $4.71B | $11.18B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $29.41, up 2.69% today, near its consensus price target low of $29.00. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.09B in 2025 with net income surging to $244.62M, reflecting a robust profit margin expansion. Recent earnings beats in Q4 2025 and Q1 2026 support positive sentiment, while the company expanded Box Zones globally to enhance data governance (Business Wire, 2026-06-30).
The outlook remains favorable with a $37.00 analyst price target implying 26% upside, backed by 60.7% buy ratings. Key risks include high P/E of 45.95 suggesting premium valuation, competitive pressures in content management, and debt levels requiring monitoring. Positive cash flow trends and strategic expansions provide growth catalysts, but investors should weigh valuation concerns against earnings momentum.
Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.
The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
